CRBP

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered in Norwood, Massachusetts, focused on developing precision medicines that target the endocannabinoid system. The company's pipeline includes drug candidates for the treatment of inflammatory and fibrotic diseases, including cystic fibrosis, systemic lupus erythematosus, and systemic sclerosis. Corbus leverages its understanding of cannabinoid receptor biology to develop novel therapeutics that modulate immune and inflammatory responses. The company is advancing multiple clinical programs aimed at addressing significant unmet medical needs in rare and serious diseases.